MA30671B1 - Vaccins contre le paludisme - Google Patents

Vaccins contre le paludisme

Info

Publication number
MA30671B1
MA30671B1 MA31672A MA31672A MA30671B1 MA 30671 B1 MA30671 B1 MA 30671B1 MA 31672 A MA31672 A MA 31672A MA 31672 A MA31672 A MA 31672A MA 30671 B1 MA30671 B1 MA 30671B1
Authority
MA
Morocco
Prior art keywords
protein
particle
hepatitis
antigen
vaccines against
Prior art date
Application number
MA31672A
Other languages
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Christian F Ockenhouse
Anjali Yadava
Original Assignee
Glaxosmithkline Biolog Sa
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1A external-priority patent/GB0614254D0/en
Priority claimed from GB0614473A external-priority patent/GB0614473D0/en
Priority claimed from GB0614476A external-priority patent/GB0614476D0/en
Priority claimed from GB0615115A external-priority patent/GB0615115D0/en
Application filed by Glaxosmithkline Biolog Sa, Us Army filed Critical Glaxosmithkline Biolog Sa
Publication of MA30671B1 publication Critical patent/MA30671B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une particule lipoprotéique innovante, des procédés de préparation et de purification de celle-ci, son utilisation en médecine, en particulier pour la prévention des infections paludéennes, des compositions/vaccins contenant la particule ou des anticorps contre la particule protéique tels que des anticorps monoclonaux ou polyclonaux et leur utilisation, en particulier dans des buts thérapeutiques. L'invention concerne en particulier une particule protéique immunogène qui comprend les monomères suivants: (a) une protéine de fusion comprenant des séquences dérivées d'une protéine CS de P. vivax et de l'antigène S de l'hépatite B (CSV-S), et (b) une protéine de fusion comprenant des séquences dérivées d'une protéine CS de P. falciparum et de l'antigène S de l'hépatite B (RTS), et (c) facultativement l'antigène S dérivé de l'hépatite B.
MA31672A 2006-07-18 2009-02-27 Vaccins contre le paludisme MA30671B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0614254.1A GB0614254D0 (en) 2006-07-18 2006-07-18 Vaccine
GB0614473A GB0614473D0 (en) 2006-07-20 2006-07-20 Vaccines
GB0614476A GB0614476D0 (en) 2006-07-20 2006-07-20 Vaccine
GB0615115A GB0615115D0 (en) 2006-07-28 2006-07-28 Vaccines

Publications (1)

Publication Number Publication Date
MA30671B1 true MA30671B1 (fr) 2009-08-03

Family

ID=38957130

Family Applications (2)

Application Number Title Priority Date Filing Date
MA31672A MA30671B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme
MA31671A MA30670B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA31671A MA30670B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme

Country Status (22)

Country Link
US (2) US9364525B2 (fr)
EP (2) EP2040742B1 (fr)
JP (2) JP5222289B2 (fr)
KR (2) KR20090092752A (fr)
AR (1) AR061894A1 (fr)
AU (2) AU2007276219B2 (fr)
BR (2) BRPI0715581A2 (fr)
CA (2) CA2657353A1 (fr)
CO (2) CO6150187A2 (fr)
CR (2) CR10555A (fr)
EA (2) EA200900032A1 (fr)
ES (2) ES2437082T3 (fr)
IL (2) IL196410A0 (fr)
MA (2) MA30671B1 (fr)
MX (2) MX2009000655A (fr)
NO (2) NO20090178L (fr)
NZ (2) NZ574239A (fr)
PE (1) PE20080428A1 (fr)
SG (2) SG173377A1 (fr)
TW (1) TW200819462A (fr)
WO (2) WO2008009652A2 (fr)
ZA (1) ZA200900386B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
AU2002365366B2 (en) 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US9364525B2 (en) * 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
WO2009071613A2 (fr) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccin
WO2009080803A1 (fr) 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccins contre la malaria
US8501926B2 (en) * 2008-09-24 2013-08-06 The Johns Hopkins University Malaria vaccine
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
US8784832B2 (en) 2011-08-19 2014-07-22 University Of South Florida (A Florida Non-Profit Corporation) Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123412A1 (fr) * 2012-02-17 2013-08-22 Children's Medical Center Corporation Antigènes trap à conformation stabilisée
WO2014111733A1 (fr) * 2013-01-21 2014-07-24 Isis Innovation Limited Composition et ses applications
EP3213638A1 (fr) 2016-03-01 2017-09-06 Coöperatie Avebe U.A. Analogue de fromage vegan
GB201608821D0 (en) * 2016-05-19 2016-07-06 Isis Innovation Vaccines
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
WO2018130871A1 (fr) * 2016-12-23 2018-07-19 The Walter And Eliza Hall Institute Of Medical Research Système, procédé, appareil et test de diagnostic pour plasmodium vivax

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
EP0229829B1 (fr) * 1985-07-12 1995-02-22 New York University Antigene de peptides immunogeniques correspondant a la proteine du circumsporozoit plasmodium vivax
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
US4997647A (en) * 1987-03-30 1991-03-05 New York University Vaccine against the sporozoite stage of malaria
EP0362278A4 (fr) 1987-06-05 1990-05-14 Us Health Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4977647A (en) * 1989-10-27 1990-12-18 D.B. Industries, Inc. Double locking snap hook
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AU2927892A (en) * 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
CA2138997C (fr) 1992-06-25 2003-06-03 Jean-Paul Prieels Composition vaccinale qui contient des adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
DE69434221T2 (de) * 1993-09-10 2006-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bindungsdomänen von Plasmodius Vivax und Plasmodium Falciparum Erythrozyten bindenden Proteinen
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20030133944A1 (en) 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CN1168702C (zh) 1998-06-30 2004-09-29 Om药业 酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物
KR20000020497A (ko) 1998-09-21 2000-04-15 임채승 말라리아의 검출방법
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU1600401A (en) * 1999-11-12 2001-06-06 Chinese University Of Hong Kong, The Malaria vaccine
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
EP1201250A1 (fr) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
KR20040043129A (ko) 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
WO2004113369A1 (fr) 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh Nouvelle variante de la proteine de surface (hbsag-) du virus de l'hepatite b
CA2528511C (fr) 2003-06-20 2015-11-03 The Trustees Of The University Of Pennsylvania Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
US20050233435A1 (en) * 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
WO2006088597A2 (fr) * 2005-01-18 2006-08-24 Walter Read Army Institute Of Research Proteine circumsporozoite hybride de plasmodium vivax et son vaccin
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US9364525B2 (en) * 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
WO2009080803A1 (fr) * 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccins contre la malaria

Also Published As

Publication number Publication date
AR061894A1 (es) 2008-10-01
AU2007276217B2 (en) 2013-08-29
MA30670B1 (fr) 2009-08-03
NZ574239A (en) 2011-12-22
WO2008009650A3 (fr) 2008-04-10
SG173363A1 (en) 2011-08-29
CA2657353A1 (fr) 2008-01-24
EP2040742A2 (fr) 2009-04-01
NO20090178L (no) 2009-02-09
US9364525B2 (en) 2016-06-14
EA200900032A1 (ru) 2011-02-28
ES2437082T3 (es) 2014-01-08
US20100150998A1 (en) 2010-06-17
CO6150187A2 (es) 2010-04-20
PE20080428A1 (es) 2008-05-15
SG173377A1 (en) 2011-08-29
CR10555A (es) 2009-04-29
WO2008009650A2 (fr) 2008-01-24
MX2009000650A (es) 2009-07-02
AU2007276219B2 (en) 2013-10-03
ES2525732T3 (es) 2014-12-29
KR20090092752A (ko) 2009-09-01
IL196471A0 (en) 2011-08-01
NZ574238A (en) 2012-02-24
BRPI0715581A2 (pt) 2013-04-24
US9592282B2 (en) 2017-03-14
JP2009543846A (ja) 2009-12-10
EP2040743A2 (fr) 2009-04-01
AU2007276217A8 (en) 2009-02-26
ZA200900386B (en) 2014-03-26
WO2008009652A3 (fr) 2008-05-08
JP5592110B2 (ja) 2014-09-17
WO2008009652A2 (fr) 2008-01-24
KR20090094213A (ko) 2009-09-04
TW200819462A (en) 2008-05-01
EP2040743B1 (fr) 2013-10-02
CR10561A (es) 2009-04-29
JP5222289B2 (ja) 2013-06-26
MX2009000655A (es) 2009-07-02
CA2657279A1 (fr) 2008-01-24
AU2007276219A1 (en) 2008-01-24
AU2007276217A1 (en) 2008-01-24
US20100062028A1 (en) 2010-03-11
IL196410A0 (en) 2011-08-01
JP2009543569A (ja) 2009-12-10
EA200900033A1 (ru) 2009-12-30
CO6150189A2 (es) 2010-04-20
NO20090177L (no) 2009-02-16
EP2040742B1 (fr) 2014-10-29
BRPI0714326A2 (pt) 2013-05-07

Similar Documents

Publication Publication Date Title
MA30671B1 (fr) Vaccins contre le paludisme
Wright et al. Plasmodium falciparum erythrocyte invasion: combining function with immune evasion
Castellanos-Gonzalez et al. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis
Radocha et al. Monoclonal antibodies and antibody drug conjugates in multiple myeloma
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
Taechalertpaisarn et al. Biochemical and functional analysis of two Plasmodium falciparum blood-stage 6-cys proteins: P12 and P41
MA30359B1 (fr) Composition pharmaceutique a liberation prolongee sur la base d'un systeme de liberation comprenant un polymere soluble dans l'acide et un polymere dependant du ph
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
Kengne-Ouafo et al. Immune responses to the sexual stages of Plasmodium falciparum parasites
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
MA32030B1 (fr) Vaccins anti-malaria
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
MA27699A1 (fr) Vaccin contre vhc
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA32821B1 (fr) Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)
Vigdorovich et al. Coimmunization with preerythrocytic antigens alongside circumsporozoite protein can enhance sterile protection against Plasmodium Sporozoite infection
Ord et al. Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design
Ouédraogo et al. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
Mehrizi et al. Th1 immune response to Plasmodium falciparum recombinant thrombospondin‐related adhesive protein (TRAP) antigen is enhanced by TLR3‐specific adjuvant, poly (I: C) in BALB/c mice
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.
Tamborrini et al. The malaria blood stage antigen Pf CyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals
US10344082B2 (en) Anti-parasitic complexes